5-MeO-DPT, alternatively referred to as 5-methoxy-N,N-Dipropyltryptamine, is a designer drug with psychedelic and entheogenic properties.

IUPAC name
CAS Number69496-75-9 
PubChem CID14011047
CompTox Dashboard (EPA)DTXSID70219723
Chemical and physical data
Molar mass274.408 g·mol−1


Its complete chemical nomenclature is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine, belonging to the category of tryptamine derivatives.


There is limited knowledge regarding the subjective effects of 5-MeO-DPT, but its characteristics are likely akin to other psychedelic tryptamines/indoles such as 5-MeO-DiPT, 5-MeO-DMT, or DPT. However, it’s important to note that the durations of these mentioned substances can differ significantly.


5-MeO-DPT is taken orally and is typically fully effective at dosages ranging from 3 to 10 mg. Its effects typically commence within three hours and generally persist for around 4 hours.


In the United States, 5-MeO-DPT is classified as a Schedule I controlled substance due to its status as a positional isomer of 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).


  • What is 5-MeO-DPT?
  • 5-MeO-DPT, also known as 5-methoxy-N, N-Dipropyltryptamine, is a designer drug classified as a psychedelic and entheogenic substance. It is a derivative of the tryptamine class.
  • What is the full chemical name of 5-MeO-DPT?
  • The complete chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine.
  • How does 5-MeO-DPT compare to other psychedelic tryptamines?
  • Although limited information is available about the subjective effects of 5-MeO-DPT, it is likely comparable to other psychedelic tryptamines, such as 5-MeO-DiPT, 5-MeO-DMT, or DPT, which are also classified as psychedelic tryptamines/indoles.
  • What is the typical dosage and duration of 5-MeO-DPT effects?
  • In most cases, a fully effective dosage of 5-MeO-DPT falls within the range of 3-10 mg. Effects usually manifest within three hours and can last around four hours.
  • Is 5-MeO-DPT legal in the United States?
  • No, 5-MeO-DPT is considered a Schedule I controlled substance in the United States. It falls under this classification due to its similarity to 5-Methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT).


  1. Schulze-Alexandru M, Kovar KA, Vedani A (December 1999). “Quasi-atomistic Receptor Surrogates for the 5-HT2A Receptor: A 3D-QSAR Study on Hallucinogenic Substances”. Quantitative Structure-Activity Relationships. 18 (6): 548–560. CiteSeerX doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B.
  2. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ (July 2011). “Abuse liability profile of three substituted tryptamines”. The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 280–9. doi:10.1124/jpet.111.179705. PMC 3126641. PMID 21474568.
  3. Glennon RA, Gessner PK (April 1979). “Serotonin receptor binding affinities of tryptamine analogues”. Journal of Medicinal Chemistry. 22 (4): 428–32. doi:10.1021/jm00190a014. PMID 430481.
  4. Halberstadt AL, Geyer MA (September 2011). “Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens”. Neuropharmacology. 61 (3): 364–81. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631. PMID 21256140.
  5. Gessner PK, Godse DD, Krull AH, McMullan JM (March 1968). “Structure-activity relationships among 5-methoxy-n,n-dimethyltryptamine, 4-hydroxy-n,n-dimethyltryptamine (psilocin) and other substituted tryptamines”. Life Sciences. 7 (5): 267–77. doi:10.1016/0024-3205(68)90200-2. PMID 5641719.
  6. Lyon RA, Titeler M, Seggel MR, Glennon RA (January 1988). “Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens”. European Journal of Pharmacology. 145 (3): 291–7. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
  7. Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). “Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes”. Psychopharmacology. 231 (21): 4135–44. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
  8. Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). “Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities”. Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
  9. Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). “Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry”. Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.
  10. Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). “Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry”. Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.
  11. Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). “5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate”. Acta Crystallographica Section E. 77 (Pt 5): 522–526. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.
  12. “Lists of: Scheduling Actions Controlled Substances Regulated Chemicals” (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.

Leave a Comment

Your email address will not be published. Required fields are marked *